Tsingke Biotechnology Secures RMB 400 Million Series B Funding to Accelerate 'Gene Factory' Development

Beijing Tsingke Biotechnology Co., Ltd. (“Tsingke Biotechnology”), a leading domestic gene synthesis enterprise, has recently secured another RMB 400 million in financing. This round was co-led by Henan Investment Group Huirong Fund and Fortune Capital, with participation from Kai Lian Capital, Qingsong Capital, Zhongyuan Asset, and Jinyu Maowu Investment Management. Huasheng Capital and Kaicheng Capital served as financial advisors. The funds will be primarily used to increase R&D investment in Tsingke Biotechnology’s gene factory, upgrade its technology platforms, expand its talent team, and advance its international operational layout, aiming to build an intelligent and automated production platform that meets global standards.

In May 2022, China’s 14th Five-Year Plan sounded the clarion call for a comprehensive entry into the era of the “bioeconomy.” The plan proposes accelerating the enhancement of biotechnological innovation capabilities, expediting the widespread empowerment of industries such as healthcare, agriculture, energy, and environmental protection by biotechnology, and promoting the diversified development of the bioeconomy. As a critical underlying enabling technology of the bioeconomy, gene synthesis will play a pivotal role in driving and facilitating technological advancement. According to forecasts by the Innovation-Driven Development Center of the National Development and Reform Commission (NDRC), the total scale of the bioeconomy is expected to reach RMB 22 trillion by 2025. As the basic unit of genetic material, genes are reshaping the world in the bioeconomy era, transforming human production and lifestyles, and achieving significant cross-sector integration among biology, information, and materials. Consequently, the entire industry’s demand for gene synthesis, as an enabling technology, has grown significantly. According to the “Oligonucleotide Synthesis Market 2021” report published by Markets and Markets Research, the global market size for gene synthesis is projected to exceed RMB 100 billion by 2026.

Beijing Tsingke Biotechnology Co., Ltd. is a vertically integrated gene synthesis platform enterprise with an independent full industry chain. Its business scope covers three major areas: synthetic genomics products and services, life science reagents and equipment, and biomanufacturing CXO services. Tsingke Biotechnology integrates synthetic raw materials, synthesis instruments and equipment, as well as synthesis technologies and services, achieving self-aggregation of production factors for its "gene factory." It stands at the forefront of the domestic industry in building a complete gene synthesis industry chain, possessing significant technological and cost advantages. Leveraging innovative intelligent gene molecular splitting and assembly technologies, combined with AI algorithms from its TSINGKE HELIXTECH system, Tsingke Biotechnology connects raw materials, equipment, and processes to establish intelligent production lines. Coupled with precise genetic testing and quality control technologies, this enables low-cost, high-efficiency, and high-quality synthesis services. In terms of service network, Tsingke Biotechnology has established eight wholly-owned subsidiaries, one holding subsidiary, and 17 branch offices across China, building a robust network system and proprietary logistics infrastructure. Its business coverage extends to over 80% of major cities in China, as well as markets in Europe, the United States, and Southeast Asia, enabling rapid response to customer needs and serving nearly 200,000 users worldwide.

Steady growth is the main theme for Tsingke Biotechnology. Following its Series A financing, the company has achieved a series of significant milestones, including the signing of a strategic cooperation agreement worth hundreds of millions of yuan for small nucleic acid synthesis, the commencement of operations at the new Hubei Tsingke molecular reagent facility, the launch of its independently developed automated oligonucleotide synthesis production line in Tianjin, and the opening of the Suzhou Zixi modified probe production base. Furthermore, Tsingke Biotechnology has established an in-depth collaboration with Academician Zheng Yuguo, leveraging its strengths in gene synthesis to deeply engage in synthetic biology manufacturing.

Ma Shijin, Founder, Chairman, and General Manager of Tsingke Biotechnology Co., Ltd., stated: “We sincerely appreciate the recognition and support from various professional investment institutions. Since our inception, we have targeted the vast growth potential of the gene synthesis industry and firmly pursued a path of independent research and development as well as integrated innovation. In summary, the company’s development trajectory has evolved from ‘synthesis technology’ to a ‘synthesis platform,’ and further to an intelligent ‘gene production factory’ with independently constructed full production factors. Over the years, the growth of the bioeconomy and life sciences sector has driven Tsingke’s rapid expansion, while Tsingke Biotechnology’s innovative technologies, scale advantages, and cost efficiencies have continuously contributed back to the industry’s development.” Du Jun, Vice President of Strategy and Technology, also noted that this round of financing will further promote the company’s strategic in-depth layout in technological innovations for high-throughput, high-capacity, and high-quality gene synthesis, with a focus on cultivating and establishing production capacity and systems in biomedical application areas such as small nucleic acid drugs, cell and gene therapy (CGT), and biomanufacturing.

Dr. Ge Dangqiao, Deputy General Manager of Henan Investment Group Huirong Fund Management Co., Ltd., stated: "In recent years, Henan Investment Group has actively positioned itself in the bio-industry. In 2022, the Henan Emerging Industry Guidance Fund under our management established a synthetic biology special sub-fund with a target size of RMB 1.5 billion. As a platform enterprise in the field of gene synthesis, Tsingke Biotechnology operates upstream in the bio-industry, providing foundational technologies and services to the entire sector. Playing the role of a 'water seller,' it serves as a supporting force for the future explosive growth of the synthetic biology and gene therapy industries. More importantly, Tsingke Biotechnology emphasizes enhancing its independent innovation capabilities and has achieved full industry chain layout. By seizing opportunities arising from the acceleration of domestic substitution in core equipment within the biopharmaceutical industry and synthetic biology manufacturing, the company boasts significant potential for future business expansion and limitless market space."

Dr. Xu Yuanping, Managing Director of Fortune Capital, stated: “As an investment institution with years of deep engagement in the healthcare sector, we place greater emphasis on the fundamental drivers underpinning industry growth. Looking ahead, the life sciences field—spanning research, diagnostics, therapeutics, and manufacturing—will comprehensively enter a gene-led molecular era. As a flagship company in the gene synthesis industry, Tsingke Biotechnology Co., Ltd. possesses advanced in-house R&D capabilities across foundational elements (synthetic raw materials, instrumentation for synthesis, and synthesis processes). Its solid accumulation of expertise and forward-looking strategic layout serve as critical engines driving the company’s development.”

Zhou Lixin, Managing Director at Kairui Capital, stated: “In addition to its leading scale advantage in the gene synthesis industry, Tsingke Biotechnology offers comprehensive coverage of gene synthesis technologies. The company has long been committed to the independent R&D of synthetic instruments, raw materials and vectors, separation and purification technologies, and automated production lines. This accumulation of technological and equipment achievements over many years will ultimately enable the enterprise to achieve multi-scenario business coverage, offering substantial room for expansion.”

Dr. Sui Xiao, Chairman of Qingsong Capital, stated: “Qingsong Capital focuses on industries such as healthcare. Leveraging its advantages across the entire gene synthesis industry chain, Tsingke Biotechnology has established a comprehensive gene synthesis platform. We are highly optimistic about their prospects and hope to empower the company to accelerate its path to an initial public offering.”

Wang Wenli, General Manager of the Investment Banking Division at Zhongyuan Asset, stated: “Zhongyuan Asset is committed to serving the real economy. By investing in platform enterprises such as Tsingke Biotechnology Co., Ltd., we aim to integrate advanced technologies and research teams to support industrial development in Henan Province.”

Wang Dong, a partner at Jinyu Maowu Investment Management, stated that the medical, pharmaceutical, and broader healthcare industry has long been one of Jinyu Maowu’s core investment sectors. He expressed great honor in participating in this round of financing for Tsingke Biotechnology. During their visits to industry clients, Tsingke’s product quality and service efficiency received high praise from customers. Among these existing customers with strong reputations, Tsingke has been able to continuously develop new business collaborations, demonstrating significant potential. We are very optimistic about this virtuous cycle and business model characterized by continuously decreasing marginal costs. Under the leadership of its management team, Tsingke Biotechnology is certain to achieve new breakthroughs.

Dr. Duan Zhigang, Partner at Huasheng Capital, stated: “In today’s era of booming development in the biotechnology industry, capabilities in gene synthesis and sequencing serve as the ‘primary driving force’ for industrial growth. Much like the genes it synthesizes, Tsingke Biotechnology is continuously advancing with higher throughput, greater capacity, and enhanced intelligence. Huasheng Capital is honored to once again serve as the financial advisor, and even more privileged to have witnessed Tsingke Biotechnology’s visionary strategic layout gradually become a reality. Throughout its Series A and current funding rounds, Tsingke Biotechnology has consistently secured steadfast support from leading investment institutions. Looking ahead, we believe that Tsingke Biotechnology will achieve solid and substantial progress in gene synthesis and related application fields.”

Dr. Zou Guowen, Founder of Kaicheng Capital, stated: “Tsingke Biotechnology is an intelligent gene factory platform in China that integrates the production of synthetic raw materials, the development of synthesis equipment and processes, and automated manufacturing. It possesses advanced design, synthesis, and assembly technologies, along with a comprehensive gene synthesis platform system. The company features a multi-tiered product portfolio covering all key segments, a robust service network, and an experienced management team with exceptional execution capabilities. We believe that Tsingke Biotechnology will further leverage its advantages through its ‘gene factory’ model, continuously breaking new ground to provide fundamental impetus for the development of biopharmaceuticals, bio-manufacturing, environmental protection, and other fields.”

In the future, Tsingke Biotechnology will further increase its investment in technological research and development, leverage the advantages of intelligent, customized, and large-scale operations of its Gene Factory, accelerate the expansion of Gene Factory applications across diverse scenarios, and contribute to the life sciences, healthcare, and related industries.